Better Buy: Canopy Growth (TSX:WEED) or Aurora Cannabis (TSX:ACB)?

Aurora Cannabis (TSX:ACB)(NYSE:ACB) and Canopy Growth (TSX:WEED) (NYSE:CGC) are strong marijuana players. Let’s find out which one is a better buy?

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

For investors, it’s really tough to know when a stock has reached its peak and when it’s bottomed out. For that same reason, it’s not easy to pick a marijuana stock when some players are doing so well and others are lagging behind.

But if you have a long-term perspective, this decision becomes much easier. Let’s take a deeper look at Aurora Cannabis (TSX:ACB)(NYSE:ACB) and Canopy Growth Corp. (TSX:WEED) (NYSE:CGC) — the two biggest marijuana stocks — to analyze their business potential and long-term value.

Canopy Growth

Canopy Growth is one of the few weed stocks with a solid foundation to grow its business and reward investors in the long run.

Canopy’s market size, capacity to ramp up production and diversity of product offerings make it a much stronger player. The company currently operates weed-growing facilities with over 2.4 million square feet of space.

But the producer has been expanding its operations quickly, which will deliver the potential to manage more than five million square feet of production space by next year. In the latest development, Canopy Growth acquired a hemp licence in New York State, as it plans to build an extraction and manufacturing facility.

One of the largest alcoholic beverage giants, Constellation Brands, last year raised its stake in the company to USD$4 billion, acquiring a nearly 40% stake in Canopy. Helped by these positive developments, Canopy Growth has surged more than 60% this year, outperforming its peers massively.

Aurora Cannabis

Aurora Cannabis has been in the headlines during the past one year due to its massive deal activity. The company bought MedReleaf Corp. and CanniMed Therapeutics last year, consolidating Aurora’s market position in the medical segment.

Aurora operates in 21 countries with a strong presence in the European Union. It expects its global medical cannabis business to accelerate significantly in the coming years. Aurora shares jumped more than 7% today after the company announced that billionaire investor Nelson Peltz is joining the company as a strategic adviser.

Peltz, whose New York-based Trian Fund Management LP has more than $10 billion under management, will advise Aurora on “potential partnerships with leading corporations,” the company said in a statement today.

“Nelson is a globally recognized business visionary with a strong track record of constructive engagement to generate accelerated, profitable growth and shareholder value across many verticals of great interest to us,” Aurora Chief Executive Officer Terry Booth said in the statement.

Bottom line

Both Canopy and Aurora are two top pot stocks that you can consider to keep in your portfolio. No doubt Canopy has had a very powerful rally in 2019 after posting 60% gains, but I still believe there is a further upside if the company continues on its growth path.

Aurora, on the other hand, has a much bigger short-term upside potential as the company looks for a strategic partnership with a top consumer brand. You can divide your investment equally between these two names to hedge your bets.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Haris Anwar has no position in the stocks mentioned in this report.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »